Previous 10 | Next 10 |
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming inves...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Samir Gharib, President and Chief Financial Officer, will...
Abstract Accepted for Oral Presentation at International Congress of Endocrinology (ICE 2022) Appointment of P.J. Ramtin as Senior Vice President of Business Operations Expansion of Tildacerfont Patent Portfolio Estate with Key Method of Use Patents Spruce ...
Gainers: Turning Point Therapeutics (TPTX) +116%. Amylyx Pharmaceuticals (AMLX) +27%. Yumanity Therapeutics (YMTX) +11%. Amarin (AMRN) +9%. Galecto (GLTO) +8%. Losers: Novavax (NVAX) -13%. Rallybio (RLYB) -13%. Invitae (NVTA) -9%. Spruce Bioscience...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming inves...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation...
Spruce Biosciences press release (NASDAQ:SPRB): Q1 GAAP EPS of -$0.50 misses by $0.06. Cash, cash equivalents and investments as of March 31, 2022, were $108.9 million. For further details see: Spruce Biosciences GAAP EPS of -$0.50 misses by $0.06
25% Enrollment Achieved in CAHmelia-203 Study for Adult Classic CAH; On Track to Report Topline Data in 2H 2023 Debt Facility with Silicon Valley Bank Amended to Provide Up to $10 Million Credit Line in 2022 Tildacerfont Patent Portfolio Estate Expanded with Key Method...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming inves...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Libbie Mansell, Ph.D., M.B.A., R.A.C., has been appointed ...
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Spruce Biosciences Inc. Website:
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Busines...
Pairs Spruce’s Investigational Product Candidate, Tildacerfont, with HMNC’s Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF 1 Receptor Antagonism Provides Spruce with Option to In-License Exclusive Worldwide ...
Significant Reduction in Dehydroepiandrosterone Sulfate ( DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed Tildacerfont was Well-Tolerated with No Safety Signals ...